DBV Technologies reported positive top‑line results from Vitesse, a pivotal Phase III trial of the Viaskin peanut epicutaneous immunotherapy patch in children aged 4–7. The trial met its primary endpoint: 46.6% of children in the Viaskin arm met responder criteria at 12 months versus 14.8% with placebo (difference 31.8%, p=0.001). The company plans a U.S. BLA submission in the first half of next year and is pursuing approvals in other jurisdictions.